KRAS and lung cancer: However, pharmacologic inhibition of FAK kinase activity suppressed KRAS-driven lung adenocarcinomas (Konstantinidou et al., 2013), suggesting an involvement of FAK kinase activity in KRAS-driven lung cancer.